Overview

Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma

Status:
Unknown status

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

To evaluate the complete clinical response rate according to the International Working Group criteria with a consolidation treatment with 90Y-ibritumomab tiuxetan (Zevalin®) in patients with high-risk follicular lymphoma with either partial or complete response to R-CHOP induction chemotherapy

Phase:

Phase 2

Details

Lead Sponsor:

Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas

Treatments:

Antibodies, Monoclonal